Background Endovascular therapy (EVT) is standard treatment for large vessel occlusion in patients with a National Institutes ...
Background The presence of a coincident intracranial aneurysm (CIA) on the target vessel of patients undergoing mechanical thrombectomy (MT) for acute ischemic stroke (AIS) poses challenges, as the ...
Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...
The $550 million tuck-in deal is slated to close between late April and the end of October, during the first half of Medtronic’s 2027 fiscal calendar. The medtech giant described Scientia’s catalog as ...
Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...
Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology. New data from the global phase 3 OCEANIC-STROKE ...
Hello. Good morning and good afternoon, everybody, and welcome to our investor webinar on the results of the OCEANIC-STROKE Phase III trial directly live from ISC 2026 in New Orleans. So my name is ...
Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared ...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke ...
Boston Scientific has agreed to acquire Penumbra in a cash and stock deal worth roughly $14.5 billion. The transaction values Penumbra at $374 per share. Penumbra has developed a comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results